Developer docs
API playgroundTry for free, no card

Search company profiles

iXCells Biotechnologies

Full company profile

uuid0006ygg

Namestring
iXCells Biotechnologies
Legal namestring
iXCells Biotechnologies
Company typeenum
Private
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
iPSC cell products, primary cell isolation, preclinical CRO services, CRISPR genome editing, cell culture reagents
Industry3 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medical Laboratories621511
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Medical Laboratories8071
Product category
Preclinical Drug Discovery Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Cell Products Sales
TypeOne Time License
Description

Sale of iPSC-derived cells, human primary cells, and animal primary cells. Products are cryopreserved and shipped for research use.

ixcellsbiotech.com
2Cell Media & Reagents
TypeOne Time License
Description

Specialized culture media and reagents for cell growth, differentiation, and maintenance.

ixcellsbiotech.com
3Preclinical CRO Services
TypeProfessional Services
Description

Fee-for-service including iPSC reprogramming, genome editing, differentiation services, custom cell isolation, and assay services.

ixcellsbiotech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Pricing details4 tiers
1Human Astrocytes iPSC-derived
ModelUnit PricingBilling cadencePay-as-you-go
Notes

SKU 40HU-008: 1M cells at $1,081, 2M cells at $1,444. Cryopreserved format.

ixcellsbiotech.com
2Human Motor Neurons iPSC-derived
ModelUnit PricingBilling cadencePay-as-you-go
Notes

SKU 40HU-005: 1M cells at $739, 2M cells at $1,392, 4M cells at $2,361. Cryopreserved format.

ixcellsbiotech.com
3Human PBMCs Cryopreserved
ModelUnit PricingBilling cadencePay-as-you-go
Notes

SKU 10HU-003: Range from 5M cells at $81 to 500M cells at $1,159. Multiple package sizes available.

ixcellsbiotech.com
4Cell Media & Reagents
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Media products range from $95 to $360. Growth factors and supplements available.

ixcellsbiotech.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

iXCells Biotechnologies supplies iPSC-derived cells, primary human and animal cells, and cell culture media/reagents, and provides preclinical CRO services including iPSC reprogramming, CRISPR-based genome editing, directed differentiation, custom cell isolation, high-throughput iPSC production, and disease-specific assay services for drug discovery customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • >85% HB9 positive motor neurons; >90% ISL1 positive cells
+3 more records
Product overview1 text field

iXCells Biotechnologies is a preclinical drug discovery company offering a comprehensive portfolio of cell products and CRO services centered on iPSC technology and primary cell models. The product portfolio consists of four main cell product categories (iPSC-derived cells, human primary cells, animal primary cells, and cell media & reagents) complemented by a suite of service offerings. The iPSCore platform serves as the unified platform combining iPSC generation, genome editing, differentiation, and high-throughput screening capabilities. The cell products span neurons (motor, cortical, dopaminergic, sensory, glutamatergic, GABAergic), glial cells (astrocytes, Schwann cells), muscle cells (skeletal myoblasts), and various primary cells from human and animal sources. Services include custom iPSC generation, CRISPR-based genome editing, directed differentiation, custom cell isolation, and high-throughput iPSC production. The company focuses on disease-relevant, patent-derived models for drug discovery and disease understanding, with particular strength in neurological disease models including ALS, Parkinson's, and Alzheimer's.

Product and service12 records
1iPSC-derived Cells
CategoryiPSC-derived Cell Products
Description

iPSC-derived human cell products including motor neurons, dopaminergic neurons, cortical neurons, sensory neurons, astrocytes, microglia, cardiomyocytes, hepatocytes, and other lineages for disease modeling and drug screening. For pharmaceutical, biotechnology, and academic researchers.

2Human Primary Cells
CategoryPrimary Cell Products
Description

Primary human cells isolated from various tissues and disease backgrounds, supplied as cryopreserved or fresh preparations for research applications. For researchers requiring primary human cellular models.

3Animal Primary Cells
CategoryPrimary Cell Products
Description

Primary animal cells (mouse, rat, and other species) for in vivo-correlative in vitro studies and preclinical research applications. For academic and industry preclinical researchers.

4Cell Media and Reagents
CategoryCell Culture Reagents
Description

Cell culture media, differentiation kits, and reagents formulated to support iPSC maintenance, differentiation, and primary cell culture. For researchers using the company's cell products or running in-house culture workflows.

5iPSC Generation Services
CategoryCRO Services
Description

Custom iPSC reprogramming from customer-provided somatic cells (PBMCs, fibroblasts, etc.) using non-integrating methods, with characterization and banking. For researchers needing patient- or donor-specific iPSC lines.

6Genome Editing Services
CategoryCRO Services
Description

CRISPR/Cas9-based gene knockout, knock-in, and point mutation services in iPSCs and primary cells, including clonal expansion and validation. For researchers building isogenic or disease-mutation cell models.

7iPSC Differentiation Services
CategoryCRO Services
Description

Directed differentiation of customer iPSCs into neurons, cardiomyocytes, hepatocytes, and other lineages using proprietary protocols, with characterization of marker expression and function. For researchers without in-house differentiation capacity.

8Custom Cell Isolation Services
CategoryCRO Services
Description

Custom isolation of primary cells from customer-provided or procured human or animal tissues using protocol development and cell purification workflows. For researchers requiring rare or specialized primary cell preparations.

9High-Throughput iPSC Production Services
CategoryCRO Services
Description

Scaled iPSC production and banking under standardized, quality-controlled conditions to support large-cohort or screening-scale programs. For groups running population-scale or screening studies.

10Preclinical CRO Services
CategoryCRO Services
Description

Integrated preclinical drug discovery services combining disease modeling, target validation, compound screening, and efficacy assessment using iPSC-derived and primary cell platforms. For pharmaceutical and biotech drug discovery programs.

11Assay Services
CategoryCRO Services
Description

Biological assay services including flow cytometry, immunocytochemistry, qPCR, ELISA, MEA electrophysiology, and patch clamp assays run on customer-supplied or company-provided cell models. For researchers needing outsourced assay execution and readouts.

12Antisense Oligonucleotide (ASO) Screening Services
CategoryCRO Services
Description

Disease-specific ASO screening services using iPSC-derived neuronal and other disease models, with functional readouts, for neurological and rare disease drug discovery. For antisense therapy developers and rare disease researchers.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

International collaboration to assess off-target chemotherapeutic toxicity using patient-derived organoids. Combines iXCells' cellular reprogramming expertise with Rosebud's organoid platforms.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

AI-driven analysis partnership for multi-organ toxicity profiling in oncology research. Enables personalized toxicity profiles using advanced analytics.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Market-leading iPSC-derived cell provider offering neurons, cardiomyocytes, hepatocytes, and other differentiated cell types for drug discovery. Closest direct competitor to iXCells in catalog iPSC-derived neural cells, with substantially greater scale and broader pharma penetration.

TypeDirect peer
Description

Specialty provider of iPSC-derived human cell types with strong overlap in neural cell products (motor neurons, cortical neurons, astrocytes). Competes with iXCells in the same niche of human iPSC-derived neural models for neuroscience and disease modeling.

TypeDirect peer
Description

Broad life science tools company offering primary cells, culture media, and cell isolation products that overlap with iXCells' primary cells and reagents catalog. A major competitor in the cell products and reagents category.

TypeBroad incumbent
Description

Global CDMO and cell products provider offering primary cells, media, and cell therapy manufacturing services. Overlaps with iXCells' cell products and CRO services categories but operates at a much larger scale across multiple life science segments.

TypeBroad incumbent
Description

Incumbent life science tools giant offering primary cells, reagents, media, and iPSC-related products through its bioscience brands. Competes with iXCells across the cell products and reagents catalog as part of a much broader portfolio.

TypeDirect peer
Description

iPSC-focused company offering iPSC-derived cell products, reprogramming services, and contract research. Direct competitor to iXCells in iPSC generation services and catalog iPSC-derived neural cells, with comparable specialization in neurological models.

TypeDirect peer
Description

iPSC-derived cardiac and neuronal cell provider for drug discovery and safety assessment. Competes directly with iXCells' iPSC-derived cardiomyocytes and neural cell lines for pharma preclinical screening applications.

TypeDirect peer
Description

Provider of primary human and animal cells, including specialty neural cells, for research applications. Overlaps with iXCells' primary cells catalog across multiple tissue types and species.

TypeEmerging player
Description

Specialized provider of iPSC-derived neural cells (neurons and glia) for neuroscience research and drug discovery. Closely comparable niche focus on neurological disease models, similar in size and scope to iXCells.

TypeEmerging player
Description

Synthetic biology company using proprietary cellular reprogramming technology to produce consistent human iPSC-derived cells at scale. Overlaps with iXCells' iPSC reprogramming and differentiation capabilities, with a stronger technology platform differentiation angle.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

iXCells Biotechnologies

Preclinical Drug Discovery Servicesixcellsbiotech.com

iXCells Biotechnologies firmographics

Firmographics
Name
iXCells Biotechnologies
Legal name
iXCells Biotechnologies
Website
https://ixcellsbiotech.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

iXCells Biotechnologies industry classification

Industry
Product category
Preclinical Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Medical Laboratories (621511)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)

Keywords

  • IPSC cell products
  • Primary cell isolation
  • Preclinical CRO services
  • CRISPR genome editing
  • Cell culture reagents

Where iXCells Biotechnologies is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

iXCells Biotechnologies business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Cell Products Sales: Sale of iPSC-derived cells, human primary cells, and animal primary cells. Products are cryopreserved and shipped for research use.
  2. Cell Media & Reagents: Specialized culture media and reagents for cell growth, differentiation, and maintenance.
  3. Preclinical CRO Services: Fee-for-service including iPSC reprogramming, genome editing, differentiation services, custom cell isolation, and assay services.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goHuman Astrocytes iPSC-derived
Unit PricingPay-as-you-goHuman Motor Neurons iPSC-derived
Unit PricingPay-as-you-goHuman PBMCs Cryopreserved
Unit PricingPay-as-you-goCell Media & Reagents

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

iXCells Biotechnologies product offering

Product offering

Core offering

iXCells Biotechnologies supplies iPSC-derived cells, primary human and animal cells, and cell culture media/reagents, and provides preclinical CRO services including iPSC reprogramming, CRISPR-based genome editing, directed differentiation, custom cell isolation, high-throughput iPSC production, and disease-specific assay services for drug discovery customers.

Product overview

iXCells Biotechnologies is a preclinical drug discovery company offering a comprehensive portfolio of cell products and CRO services centered on iPSC technology and primary cell models. The product portfolio consists of four main cell product categories (iPSC-derived cells, human primary cells, animal primary cells, and cell media & reagents) complemented by a suite of service offerings. The iPSCore platform serves as the unified platform combining iPSC generation, genome editing, differentiation, and high-throughput screening capabilities. The cell products span neurons (motor, cortical, dopaminergic, sensory, glutamatergic, GABAergic), glial cells (astrocytes, Schwann cells), muscle cells (skeletal myoblasts), and various primary cells from human and animal sources. Services include custom iPSC generation, CRISPR-based genome editing, directed differentiation, custom cell isolation, and high-throughput iPSC production. The company focuses on disease-relevant, patent-derived models for drug discovery and disease understanding, with particular strength in neurological disease models including ALS, Parkinson's, and Alzheimer's.

Differentiator

Problem solved

Functional benefit

Products and services

  • iPSC-derived Cells iPSC-derived human cell products including motor neurons, dopaminergic neurons, cortical neurons, sensory neurons, astrocytes, microglia, cardiomyocytes, hepatocytes, and other lineages for disease modeling and drug screening. For pharmaceutical, biotechnology, and academic researchers.
  • Human Primary Cells Primary human cells isolated from various tissues and disease backgrounds, supplied as cryopreserved or fresh preparations for research applications. For researchers requiring primary human cellular models.
  • Animal Primary Cells Primary animal cells (mouse, rat, and other species) for in vivo-correlative in vitro studies and preclinical research applications. For academic and industry preclinical researchers.
  • Cell Media and Reagents Cell culture media, differentiation kits, and reagents formulated to support iPSC maintenance, differentiation, and primary cell culture. For researchers using the company's cell products or running in-house culture workflows.
  • iPSC Generation Services Custom iPSC reprogramming from customer-provided somatic cells (PBMCs, fibroblasts, etc.) using non-integrating methods, with characterization and banking. For researchers needing patient- or donor-specific iPSC lines.
  • Genome Editing Services CRISPR/Cas9-based gene knockout, knock-in, and point mutation services in iPSCs and primary cells, including clonal expansion and validation. For researchers building isogenic or disease-mutation cell models.
  • iPSC Differentiation Services Directed differentiation of customer iPSCs into neurons, cardiomyocytes, hepatocytes, and other lineages using proprietary protocols, with characterization of marker expression and function. For researchers without in-house differentiation capacity.
  • Custom Cell Isolation Services Custom isolation of primary cells from customer-provided or procured human or animal tissues using protocol development and cell purification workflows. For researchers requiring rare or specialized primary cell preparations.
  • High-Throughput iPSC Production Services Scaled iPSC production and banking under standardized, quality-controlled conditions to support large-cohort or screening-scale programs. For groups running population-scale or screening studies.
  • Preclinical CRO Services Integrated preclinical drug discovery services combining disease modeling, target validation, compound screening, and efficacy assessment using iPSC-derived and primary cell platforms. For pharmaceutical and biotech drug discovery programs.
  • Assay Services Biological assay services including flow cytometry, immunocytochemistry, qPCR, ELISA, MEA electrophysiology, and patch clamp assays run on customer-supplied or company-provided cell models. For researchers needing outsourced assay execution and readouts.
  • Antisense Oligonucleotide (ASO) Screening Services Disease-specific ASO screening services using iPSC-derived neuronal and other disease models, with functional readouts, for neurological and rare disease drug discovery. For antisense therapy developers and rare disease researchers.

Quantifiable outcome

  • >85% HB9 positive motor neurons; >90% ISL1 positive cells
  • +3 more outcomes

Companies that use iXCells Biotechnologies

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

iXCells Biotechnologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

iXCells Biotechnologies partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Rosebud BiosciencescoreStrategic or Co-development PartnerInternational collaboration to assess off-target chemotherapeutic toxicity using patient-derived organoids. Combines iXCells' cellular reprogramming expertise with Rosebud's organoid platforms.
  • KantifycoreStrategic or Co-development PartnerAI-driven analysis partnership for multi-organ toxicity profiling in oncology research. Enables personalized toxicity profiles using advanced analytics.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

iXCells Biotechnologies competitors and assessment

Company assessment

Direct peers

  • FUJIFILM Cellular Dynamics: Market-leading iPSC-derived cell provider offering neurons, cardiomyocytes, hepatocytes, and other differentiated cell types for drug discovery. Closest direct competitor to iXCells in catalog iPSC-derived neural cells, with substantially greater scale and broader pharma penetration.
  • Axol Bioscience: Specialty provider of iPSC-derived human cell types with strong overlap in neural cell products (motor neurons, cortical neurons, astrocytes). Competes with iXCells in the same niche of human iPSC-derived neural models for neuroscience and disease modeling.
  • Stemcell Technologies: Broad life science tools company offering primary cells, culture media, and cell isolation products that overlap with iXCells' primary cells and reagents catalog. A major competitor in the cell products and reagents category.
  • REPROCELL: iPSC-focused company offering iPSC-derived cell products, reprogramming services, and contract research. Direct competitor to iXCells in iPSC generation services and catalog iPSC-derived neural cells, with comparable specialization in neurological models.
  • Ncardia: iPSC-derived cardiac and neuronal cell provider for drug discovery and safety assessment. Competes directly with iXCells' iPSC-derived cardiomyocytes and neural cell lines for pharma preclinical screening applications.
  • Cell Applications: Provider of primary human and animal cells, including specialty neural cells, for research applications. Overlaps with iXCells' primary cells catalog across multiple tissue types and species.

Broad incumbents

  • Lonza: Global CDMO and cell products provider offering primary cells, media, and cell therapy manufacturing services. Overlaps with iXCells' cell products and CRO services categories but operates at a much larger scale across multiple life science segments.
  • Thermo Fisher Scientific: Incumbent life science tools giant offering primary cells, reagents, media, and iPSC-related products through its bioscience brands. Competes with iXCells across the cell products and reagents catalog as part of a much broader portfolio.

Emerging players

  • BrainXell: Specialized provider of iPSC-derived neural cells (neurons and glia) for neuroscience research and drug discovery. Closely comparable niche focus on neurological disease models, similar in size and scope to iXCells.
  • bit.bio: Synthetic biology company using proprietary cellular reprogramming technology to produce consistent human iPSC-derived cells at scale. Overlaps with iXCells' iPSC reprogramming and differentiation capabilities, with a stronger technology platform differentiation angle.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

iXCells Biotechnologies social profiles

Digital presence

iXCells Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

iXCells Biotechnologies leadership team

Management profile

Number of profiles

iXCells Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

iXCells Biotechnologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iXCells Biotechnologies

What does iXCells Biotechnologies do?

iXCells Biotechnologies supplies iPSC-derived cells, primary human and animal cells, and cell culture media/reagents, and provides preclinical CRO services including iPSC reprogramming, CRISPR-based genome editing, directed differentiation, custom cell isolation, high-throughput iPSC production, and disease-specific assay services for drug discovery customers.

Is iXCells Biotechnologies a public or private company?

iXCells Biotechnologies is a private company. It is classified as unknown and is currently operating.

When was iXCells Biotechnologies founded?

iXCells Biotechnologies was founded in 2014. It employs 11 to 50 people.

Where is iXCells Biotechnologies based?

iXCells Biotechnologies is headquartered in San Diego, United States, in the North America region.

How does iXCells Biotechnologies make money?

Three revenue lines are on record. Cell Products Sales are the primary driver. The others are cell Media & Reagents and preclinical CRO Services.

Who are iXCells Biotechnologies's main competitors?

Direct peers on record are FUJIFILM Cellular Dynamics, Axol Bioscience, Stemcell Technologies, REPROCELL, Ncardia and Cell Applications. Broad incumbents are Lonza and Thermo Fisher Scientific. Emerging players are BrainXell and bit.bio.

Does iXCells Biotechnologies have an API?

No public API is recorded for iXCells Biotechnologies.

What industry is iXCells Biotechnologies in?

iXCells Biotechnologies's product category is Preclinical Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicaliXCells Biotechnologies joins international collaboration to evaluate chemotherapeutic toxicity in human organoidsiXCells Biotechnologies announced an international collaboration with Rosebud, Kantify, and Incite to evaluate off-target chemotherapeutic toxicities in patient-specific organoids. The project will initially focus on heart, liver, and kidney models, using patient-derived hiPSCs and AI-driven analysis to generate personalized toxicity profiles.News-MedicaliXCells Biotechnologies reaches iPSC line delivery milestone in collaboration with global biotechnology companyiXCells Biotechnologies announced delivery of over 500 characterized induced pluripotent stem cell (iPSC) lines as part of a multi-year collaboration with an unnamed global biotechnology company. The milestone demonstrates the scalability of iXCells' iPSCore platform, which achieves a 98% reprogramming success rate and produces nearly 200 lines per month, with over 700 additional lines currently in development. The company stated that this collaboration showcases its ability to deliver iPSC reprogramming at industrial scale to support drug discovery and therapeutic development.PharmiWeb.comiXCells Biotechnologies Reaches iPSC Line Delivery Milestone in Collaboration With Global Biotechnology CompanyiXCells Biotechnologies USA, Inc. announced the delivery of over 500 characterized induced pluripotent stem cell (iPSC) lines as part of a multi-year collaboration with a global biotechnology company, leveraging its iPSCore platform. The platform is delivering nearly 200 iPSC lines per month with a reprogramming success rate exceeding 98%, with more than 700 additional lines currently in development. The collaboration demonstrates iXCells' ability to deliver iPSC reprogramming at industrial scale for drug discovery applications, enabling high-throughput production of patient-derived cell models for therapeutic research.ContractpharmaiXCells Delivers 500+ Characterized iPSC Lines for Global Biotechnology CompanyiXCells Biotechnologies USA Inc. has delivered over 500 characterized induced pluripotent stem cell (iPSC) lines as part of a multi-year collaboration with a global biotechnology company. The collaboration leverages iXCells' iPSCore platform, which supports large-scale generation of patient-derived iPSC lines for drug discovery, with over 700 additional lines currently in development. The milestone demonstrates iXCells' capacity to deliver iPSC reprogramming at industrial scale while maintaining quality, reproducibility, and consistency for therapeutic development.ContractpharmaiXCells Taps Steve Smith as CEOiXCells Biotechnologies has appointed Steve Smith, formerly its Chief Commercial Officer, as the new CEO to lead the company's growth and execution of bespoke iPSC preclinical services. This leadership transition aims to support larger preclinical programs and expand collaborations with biotech and pharmaceutical partners amid increasing demand for scalable human-derived models.BioinformantInterview with Dr. Nianwei Lin, Co-Founder and President of iXCells BiotechnologiesiXCells Biotechnologies, founded in 2014, provides primary cells and iPSC-derived cells for pre-clinical drug discovery. The company offers over 70 primary cell types and iPSC-derived cell lines, including motor neurons, and provides CRO services. It plans to expand into cGMP cell therapy and ASO drug screening.CRISPR MedicinePress Release Service: iXCells Biotechnologies Expands CRISPR-Cas9 Cell Products and Genome Engineering ServicesiXCells Biotechnologies announced an expansion of its CRISPR-Cas9 cell products and genome engineering services, focusing on disease relevant iPSC derived models for neurological diseases like ALS, Alzheimer’s, Parkinson's, and others. The company provides genetically modified cell models for research and preclinical drug development, utilizing CRISPR technology under a licensing agreement.BioSpaceiXCells Biotechnologies Secures Strategic Growth Investment from Great Point PartnersiXCells Biotechnologies received a growth investment from Great Point Partners, a healthcare-focused private equity firm. The capital will fund growth initiatives to expand operational capacity, product offerings, and bioanalytical capabilities, with a focus on personalized medicine and rare diseases.Business Wire BlogiXCells Biotechnologies Secures Strategic Growth Investment from Great Point PartnersiXCells Biotechnologies received a growth investment from Great Point Partners, a healthcare-focused private equity firm. The company will use the capital to expand operational capacity, product offerings, and bioanalytical capabilities, particularly for personalized medicine and rare diseases.BioSpaceiXCells Biotechnologies Announces Strategic Initiatives to Drive Continued GrowthiXCells Biotechnologies announced growth initiatives including a cloud-based Oracle NetSuite ERP integration and hiring plans. The company expects to complete integration with a go-live date next year and has engaged corporate development advisor Wayne Vaz.